Literature DB >> 30902885

Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade.

Ying Zhu1, Jing Yang1, Da Xu1, Xiao-Mei Gao2, Ze Zhang1, Jennifer L Hsu3, Chia-Wei Li3, Seung-Oe Lim3, Yuan-Yuan Sheng1, Yu Zhang1, Jian-Hua Li1, Qin Luo2, Yan Zheng1, Yue Zhao1, Lu Lu1, Hu-Liang Jia1, Mien-Chie Hung3, Qiong-Zhu Dong1,2, Lun-Xiu Qin1,2.   

Abstract

OBJECTIVE: In the tumour microenvironment, critical drivers of immune escape include the oncogenic activity of the tumour cell-intrinsic osteopontin (OPN), the expression of programmed death ligand 1 (PD-L1) and the expansion of tumour-associated macrophages (TAMs). We investigated the feasibility of targeting these pathways as a therapeutic option in hepatocellular carcinoma (HCC) mouse models.
DESIGN: We analysed the number of tumour-infiltrating immune cells and the inflammatory immune profiles in chemically induced liver tumour isolated from wild-type and OPNknockout (KO) mice. In vitro cell cocultures were further conducted to investigate the crosstalk between TAMs and HCC cells mediated by OPN, colony stimulating factor-1 (CSF1) and CSF1 receptor (CSF1R). The in vivo efficacy of anti-PD-L1 and CSF1/CSF1R inhibition was evaluated in OPN overexpressing subcutaneous or orthotopic mouse model of HCC.
RESULTS: The numbers of TAMs, as well as the expression levels of M2 macrophage markers and PD-L1 were significantly decreased, but the levels of cytokines produced by T-helper 1 (Th1) cells were upregulated in tumour tissues from OPN KO mice compared with that from the controls. In addition, we observed a positive association between the OPN and PD-L1 expression, and OPN expression and TAM infiltration in tumour tissues from patients with HCC. We further demonstrated that OPN facilitates chemotactic migration, and alternative activation of macrophages, and promotes the PD-L1 expression in HCC via activation of the CSF1-CSF1R pathway in macrophages. Combining anti-PD-L1 and CSF1R inhibition elicited potent antitumour activity and prolonged survival of OPNhigh tumour-bearing mice. Histological, flow cytometric and ELISA revealed increased CD8+ T cell infiltration, reduced TAMs and enhanced Th1/Th2 cytokine balance in multiple mouse models of HCC.
CONCLUSIONS: OPN/CSF1/CSF1R axis plays a critical role in the immunosuppressive nature of the HCC microenvironment. Blocking CSF1/CSF1R prevents TAM trafficking and thereby enhances the efficacy of immune checkpoint inhibitors for the treatment of HCC. © Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  anti-PD-L1; hepatocellular carcinoma; immune checkpoint blockade; tumor microenvironment

Mesh:

Substances:

Year:  2019        PMID: 30902885     DOI: 10.1136/gutjnl-2019-318419

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  83 in total

Review 1.  The involvement of bioactive factors in the self-renewal and stemness maintenance of spermatogonial stem cells.

Authors:  Guoqing Yang; Yuqing He; Hao Yang
Journal:  Mol Cell Biochem       Date:  2021-01-18       Impact factor: 3.396

2.  Sequential Therapy for Hepatocellular Carcinoma after Failure of Atezolizumab plus Bevacizumab Combination Therapy.

Authors:  Masatoshi Kudo
Journal:  Liver Cancer       Date:  2021-02-15       Impact factor: 11.740

3.  IFN-α facilitates the effect of sorafenib via shifting the M2-like polarization of TAM in hepatocellular carcinoma.

Authors:  Ze Zhang; Ying Zhu; Da Xu; Tian-En Li; Jian-Hua Li; Zi-Tian Xiao; Mo Chen; Xin Yang; Hu-Liang Jia; Qiong-Zhu Dong; Lun-Xiu Qin
Journal:  Am J Transl Res       Date:  2021-01-15       Impact factor: 4.060

Review 4.  Heterogeneous responses in hepatocellular carcinoma: the achilles heel of immune checkpoint inhibitors.

Authors:  Zuyuan Lin; Di Lu; Xuyong Wei; Jianguo Wang; Xiao Xu
Journal:  Am J Cancer Res       Date:  2020-04-01       Impact factor: 6.166

5.  Predicting Non-Alcoholic Fatty Liver Disease Progression and Immune Deregulations by Specific Gene Expression Patterns.

Authors:  Fanhong Zeng; Yue Zhang; Xu Han; Min Zeng; Yi Gao; Jun Weng
Journal:  Front Immunol       Date:  2021-01-26       Impact factor: 7.561

Review 6.  Danger signals in liver injury and restoration of homeostasis.

Authors:  Hui Han; Romain Desert; Sukanta Das; Zhuolun Song; Dipti Athavale; Xiaodong Ge; Natalia Nieto
Journal:  J Hepatol       Date:  2020-05-01       Impact factor: 25.083

7.  Macrophage-derived CCL5 facilitates immune escape of colorectal cancer cells via the p65/STAT3-CSN5-PD-L1 pathway.

Authors:  Chao Liu; Zhaoying Yao; Jianing Wang; Wen Zhang; Yan Yang; Yan Zhang; Xinliang Qu; Yubing Zhu; Jianjun Zou; Sishi Peng; Yan Zhao; Shuli Zhao; Bangshun He; Qiongyu Mi; Xiuting Liu; Xu Zhang; Qianming Du
Journal:  Cell Death Differ       Date:  2019-12-04       Impact factor: 15.828

8.  Hepatic stellate cells promote intrahepatic cholangiocarcinoma progression via NR4A2/osteopontin/Wnt signaling axis.

Authors:  Chu-Yu Jing; Yi-Peng Fu; Cheng Zhou; Mei-Xia Zhang; Yong Yi; Jin-Long Huang; Wei Gan; Juan Zhang; Su-Su Zheng; Bo-Heng Zhang; Shuang-Jian Qiu
Journal:  Oncogene       Date:  2021-03-19       Impact factor: 9.867

9.  The Transcriptomic Landscape of Mismatch Repair-Deficient Intestinal Stem Cells.

Authors:  Prashant V Bommi; Charles M Bowen; Laura Reyes-Uribe; Wenhui Wu; Hiroyuki Katayama; Pedro Rocha; Edwin R Parra; Alejandro Francisco-Cruz; Zuhal Ozcan; Elena Tosti; Jason A Willis; Hong Wu; Melissa W Taggart; Jared K Burks; Patrick M Lynch; Winfried Edelmann; Paul A Scheet; Ignacio I Wistuba; Krishna M Sinha; Samir M Hanash; Eduardo Vilar
Journal:  Cancer Res       Date:  2021-03-18       Impact factor: 12.701

10.  Rational combination of an immune checkpoint inhibitor with CSF1R inhibitor-loaded nanoparticle enhances anticancer efficacy.

Authors:  Vaishali Malik; Hayat Anu Ranjani; Anujan Ramesh; Harriet Smith; Ashish A Kulkarni
Journal:  Drug Deliv Transl Res       Date:  2021-08-07       Impact factor: 4.617

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.